Clinical trials: Heart Failure With Preserved Ejection Fraction (HFPEF)
Iron Deficiency Anemia, Coronary Artery Disease
Non-Interventional Study of Ferretab® Comp. (Ferrous Fumarate + Folic Acid Prolonged-Release Capsules) Effects in Adult Patients With Iron Deficiency Anemia and Cardiovascular Disease
The goal of this observational study is to learn how well Ferretab® comp. works and how safe it is for adults with iron deficiency anemia and cardiovascular disease who are receiving treatment as part of their usual medical care.
- Conditions
- Iron Deficiency Anemia, Coronary Artery Disease, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- PROMETHEUS (NCT07753031)
- Where
- 5 sites in Russia
- Volunteers
- 389 people
- Sponsor
- Alcea
Heart Failure With Preserved Ejection Fraction (HFPEF)
This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
The SPECTRA-HFpEF Study is a randomized, double-blind, Phase 2 clinical study designed to evaluate and compare the biological effects of vicadrostat in combination with empagliflozin, empagliflozin alone, and spironolactone in…
- Trial name
- SPECTRA-HFpEF (NCT07857772)
- Testing
- empa plus vica, Comparator: empa 10 plus spironolactone
- Volunteers
- 200 people
- Sponsor
- Baim Institute for Clinical Research
Heart Failure, Heart Failure, Systolic
Predicting Heart Failure Outcomes With Biomarkers and Imaging
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- BIOPHF (NCT07332520)
- Volunteers
- 4,000 people
- Sponsor
- Xinjiang Medical University
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection…
- Trial name
- Elevate-HF (NCT07761117)
- Testing
- Elecoglipron
- Where
- 679 sites in United States, Argentina and 30 more
- Volunteers
- 6,950 people
- Sponsor
- AstraZeneca
Chronic Heart Failure
Prediabetes and Newly Diagnosed Diabetes in Chronic Heart Failure
The aim the study is to determine the prevalence of prediabetic dysglycemia and newly diagnosed diabetes among individuals with CHF(chronic heart failure) in sohag university hospital patients .
- Trial name
- NCT05090202
- Testing
- hbA1C
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Heart Failure With Preserved Ejection Fraction (HFpEF), Hypertension
Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System
This study is a prospective, double blind, self-controlled, randomized, cross-over study to evaluate the feasibility, efficacy, and safety of treating patients with Heart Failure with preserved Ejection Fraction (HFpEF)…
- Trial name
- RelieveHFpEFII (NCT06036186)
- Testing
- BaroPacing treatment, Standard treatment
- Where
- 3 sites in India
- Volunteers
- 16 people
- Sponsor
- BaroPace Inc.
Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2
Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Metabolic Effects. (KETO-HFpEF-Metabolic)
Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial effects in patients with hearth failure with reduced ejection…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2, Ketonemia
- Trial name
- NCT05159570
- Testing
- Ketone ester
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Heart Failure With Preserved Ejection Fraction, Arterial Hypertension
Ambulatory Blood Pressure in HFPEF Outcomes Global Registry
Heart failure and preserved ejection fraction (HFPEF) is a disease with increasing prevalence world wide. Due to its etiological and prognostic relationship with hypertension, it is highly interesting to know the characteristics…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Arterial Hypertension, Frailty Syndrome, Comorbidities and Coexisting Conditions
- Trial name
- HFPEFGlobal (NCT04065620)
- Testing
- ambulatory blood pressure measurement
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Hospital Clinic of Barcelona
Heart Diseases, Cardiovascular Diseases
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Conditions
- Heart Diseases, Cardiovascular Diseases, Heart Failure
- Trial name
- EvolutionHF-DE (NCT06336330)
- Where
- 47 sites in Germany
- Volunteers
- 831 people
- Sponsor
- AstraZeneca
Heart Failure, Inflammation
Colchicine in HFpEF
Heart failure is a growing epidemic that affects up to 500,000 individuals in Canada, with 50,000 new cases being diagnosed each year. Half of these will have HF with preserved ejection fraction (HFpEF).
- Conditions
- Heart Failure, Inflammation, Colchicine
- Trial name
- COLpEF (NCT04857931)
- Testing
- Colchicine
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Montreal Heart Institute
Heart Failure With Preserved Ejection Fraction
Relationship Between Ambulatory Arterial Stiffness Index and Left Ventricular Diastolic Function in Patients With HFpEF
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and…
- Trial name
- NCT05059769
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Dongying Zhang
Heart Failure With Preserved Ejection Fraction
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
A phase 1, randomized, double-blind, placebo-controlled single-ascending dose study to assess JK07 in adult subjects with heart failure with preserved ejection fraction.
- Trial name
- NCT05322616
- Testing
- JK07
- Where
- 7 sites in United States
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Incretin Therapies in Obesity-related HFpEF
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume.
- Conditions
- Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
- Trial name
- NCT07554638
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
HFpEF - Heart Failure With Preserved Ejection Fraction
The Gut Microbiota and Metabolites in HFpEF
Heart failure (HF) with preserved ejection fraction (HFpEF) has emerged as a critical public health concern. The annual mortality rate for HFpEF is approximately 15%, accompanied by a re-hospitalization rate of nearly 80%.
- Trial name
- NCT06645535
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Heart Failure With Preserved Ejection Fraction
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
- Trial name
- SP9In-HFpEF (NCT05312021)
- Testing
- IMR-687
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Exercise Capacity Before and After AF Ablation in Patients With HFpEF
In a prospective, observational pilot study of patients scheduled for an atrial fibrillation (AF) ablation at the University of Vermont Medical Center the investigators will compare exercise capacity before and four months after…
- Trial name
- NCT05376748
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Vermont
Dietary Exposure
Feasibility of Low Energy Diet in HFpEF and Type 2 Diabetes
Open, Single arm intervention, feasibility study
- Trial name
- ALLEVIATE (NCT04173117)
- Testing
- Low energy meal replacement plan (12 weeks)
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- University of Leicester
MRI Scans
New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)
This study's main specific aims are; 1. To develop robust acquisition and reconstruction methods specifically for the study of microvascular cardiac remodeling with MRI which will include very innovative quantitative perfusion…
- Trial name
- NCT04600115
- Testing
- Adenosine, Regadenoson, O-15 labeled radioactive water
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Utah
Heart Failure With Preserved Ejection Fraction
Transthyretin Cardiac Amyloidosis in HFpEF
To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon…
- Trial name
- NCT03414632
- Testing
- 99mTc-PYP
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction (HFPEF)
Association of Heterogeneous Circulating Biomarkers and Anamnestic Factors of Pregnancy Adverse Course and Outcomes With the Prognosis of Heart Failure With Preserved Ejection Fraction
The primary purpose of this study is to evaluate possible association of some heterogeneous circulating biomarkers and anamnestic factors of pregnancy adverse course and outcomes with the prognosis of heart failure with preserved…
- Trial name
- CARPO-HF (NCT06803849)
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine